Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/133612
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Holub, Katarzyna | - |
dc.contributor.author | Biete Solà, Albert | - |
dc.date.accessioned | 2019-05-21T16:54:31Z | - |
dc.date.available | 2019-05-21T16:54:31Z | - |
dc.date.issued | 2018-12-22 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | http://hdl.handle.net/2445/133612 | - |
dc.description.abstract | BACKGROUND: Systemic inflammation has long been related with adverse survival outcomes in cancer patients, and its biomarkers, such as the Neutrophil-to-Lymphocyte Ratio (NLR), are recognized as poor prognostic indicators. However, the role of eosinophils in this field has been largely overlooked. Here, we describe two new pre-treatment biomarkers, expressed as Eosinophil-to-Lymphocytes Ratio (ELR) and Eosinophil*Neutrophil-to-Lymphocytes ratio (ENLR), and we analyse their impact on prognosis of endometrial cancer (EC) patients. METHODS: A total of 163 consecutive patients diagnosed with EC and treated with postoperative radiotherapy +/- chemotherapy in our institution from January 2011 to December 2015 were evaluated. The cohort was divided in two groups applying the cut-off value of 0.1 and 0.5 according to ROC curve for pre-treatment ELR and ENLR, respectively. After patients' stratification according to the ESMO-ESGO-ESTRO modified risk assessment, subgroup analyses were conducted. RESULTS: Higher values of ELR and ENLR were associated with worse OS (p = 0.004 and p = 0.010, respectively). On univariate analysis, the factors associated with shorter OS were ELR ≥ 0.1 (HR = 2.9, p = 0.017), ENLR ≥ 0.5 (HR = 3.0, p = 0.015), advanced FIGO stage (HR = 3.4, p = 0.007), endometrioid histology (HR = 0.26, p = 0.003) and ESMO-ESGO-ESTRO high-risk (HR = 10.2, p = 0.023). On multivariate Cox regression, higher ELR and ENLR were independently associated with a worse outcome adjusted for the standardly applied prognostic factors. CONCLUSIONS: Increased values of ELR and ENLR portend worse OS in EC, especially in patients classified by the ESMO-ESGO-ESTRO guidelines as a high-risk group. To our best knowledge, this is the first report describing eosinophils-related ratios as prognostic biomarkers in malignant tumours. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s12885-018-5131-x | - |
dc.relation.ispartof | BMC Cancer, 2018, vol. 18, num. 1, p. 1280 | - |
dc.relation.uri | https://doi.org/10.1186/s12885-018-5131-x | - |
dc.rights | cc-by (c) Holub, Katarzyna et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Fonaments Clínics) | - |
dc.subject.classification | Càncer d'endometri | - |
dc.subject.classification | Marcadors tumorals | - |
dc.subject.classification | Pronòstic mèdic | - |
dc.subject.other | Endometrial cancer | - |
dc.subject.other | Tumor markers | - |
dc.subject.other | Prognosis | - |
dc.title | New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 687099 | - |
dc.date.updated | 2019-05-21T16:54:32Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30577833 | - |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
687099.pdf | 748.96 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License